Patents Issued in August 27, 2019
-
Patent number: 10392409Abstract: Functionalized fluoro polyhedral oligomeric silsesquioxane (F-POSS) materials as additives to improve liquid repellence of various polymers, the additive including at least one functionalized F-POSS material, wherein the functional group is at least one material selected from the group consisting of amines, isocyanates, epoxies, carboxylic acids, and esters.Type: GrantFiled: March 28, 2017Date of Patent: August 27, 2019Assignee: NBD NANOTECHNOLOGIES, INC.Inventors: Cheng Diao, Esra Altinok, Bong June Zhang, Perry L. Catchings, Sr.
-
Patent number: 10392410Abstract: Processes of fractionating phospholipids are disclosed. In one embodiment, the process includes placing a phospholipid containing material in contact with an adsorbent, such that the adsorbent associates with at least one phospholipid of the phospholipid containing material. The process may further include eluting the at least one phospholipid from the adsorbent.Type: GrantFiled: December 4, 2015Date of Patent: August 27, 2019Assignee: Archer Daniels Midland CompanyInventors: Greg Dodson, Doug Geier, John G. Soper, Kristen Eilts
-
Patent number: 10392411Abstract: Described herein is an enzyme-mediated approach to bioconjugation at nanoparticle (NP) surfaces. This process is enabled by a new synthetic linker compatible with the covalent attachment of alkyne modified substrates, including dyes, peptides and nucleic acids. The methods described herein specifically allow for the linkage of molecules to a DNA-functionalized nanoparticle surface. Enzymatic ligation of molecules to the terminal hydroxyl group of DNA using T4 DNA ligase is achieved through incorporation of a single monophosphate on the approaching substrate. In contrast to previous strategies, the linkers disclosed herein are compatible with alkyne modified molecules of a variety of sizes and charges indicating that the ligase minimally requires the monophosphate and the incoming hydroxyl for conjugation to be successful.Type: GrantFiled: January 10, 2019Date of Patent: August 27, 2019Assignee: University of ConnecticutInventor: Jessica Lynn Rouge
-
Patent number: 10392412Abstract: Disclosed herein, inter alia, are platinum-based compounds useful for treating cancer.Type: GrantFiled: November 2, 2016Date of Patent: August 27, 2019Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CORNELL UNIVERSITYInventors: Kathleen M. Giacomini, Swati More, Sook Wah Yee, Ethan Geier, Justin Wilson
-
Patent number: 10392413Abstract: The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R1, R2, R2?, R3, R4, X1, X2, X3, X4, Q, and n are described herein.Type: GrantFiled: December 19, 2016Date of Patent: August 27, 2019Assignee: ARDELYX, INC.Inventors: Jason Gustaf Lewis, Michael Robert Leadbetter, Jeremy Caldwell, Dean Dragoli, Noah Bell, Jeffrey W. Jacobs, Patricia Finn, Rakesh Jain, Tao Chen, Matthew Siegel
-
Patent number: 10392414Abstract: Disclosed is a compound of formula (I): wherein R1, R2, R3, and are as defined herein. Also disclosed are methods for increasing mammalian cell NAD+ production and improving mitochondrial cell densities comprising administering to a cell the compound or a salt thereof.Type: GrantFiled: July 15, 2016Date of Patent: August 27, 2019Assignee: CORNELL UNIVERSITYInventors: Anthony Sauve, Farheen Sultana Mohammed, Yue Yang
-
Patent number: 10392415Abstract: The invention relates to crystalline forms of a ?-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.Type: GrantFiled: September 30, 2016Date of Patent: August 27, 2019Assignee: Metro International Biotech, LLCInventors: David J. Livingston, Andrew Carr, Philippe Fernandes
-
Patent number: 10392416Abstract: The invention relates to crystalline forms of a ?-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.Type: GrantFiled: March 28, 2019Date of Patent: August 27, 2019Assignee: Metro International Biotech, LLCInventors: David J. Livingston, Andrew Carr, Philippe Fernandes
-
Patent number: 10392417Abstract: Processes are provided for the preparation of a stable polymorphic form C of regadenoson, the process involving steps of a) obtaining a solution of regadenoson in benzyl alcohol solvent, b) maintaining the reaction mixture of step a) to about 10° C. to about 90° C., and c) isolating the stable polymorphic form C of regadenoson. Polymorphic form C may be characterized by an x-ray powder diffraction pattern with peaks at about 6.1, 10.2, 10.6, 19.0 and 25.4.±0.2 degrees 2-theta.Type: GrantFiled: October 30, 2017Date of Patent: August 27, 2019Assignee: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Ananda Babu Thirunavakarasu, Piyush D. Fadadu, Piyush B. Thumar
-
Patent number: 10392418Abstract: The present disclosure provides a solid phase method of making oligonucleotides via sequential coupling cycles including at least one coupling of a dinucleotide dimer subunit to a free 3?-terminal group of a growing chain. The oligonucleotides include at least two nucleoside subunits joined by a N3??P5? phosphoramidate linkage. The method may include the steps of (a) deprotecting the protected 3? amino group of a terminal nucleoside attached to a solid phase support, said deprotecting forming a free 3? amino group; (b) contacting the free 3? amino group with a 3?-protected amino-dinucleotide-5?-phosphoramidite dimer in the presence of a nucleophilic catalyst to form an internucleoside N3??P5? phosphoramidite linkage; and (c) oxidizing (e.g., sulfurizing) the linkage. The compositions produced by the subject methods may include a reduced amount of one or more (N?x) oligonucleotide products. Also provided are pharmaceutical compositions including the subject oligonucleotide compositions.Type: GrantFiled: September 14, 2017Date of Patent: August 27, 2019Assignee: Geron CorporationInventor: Premchandran H. Ramiya
-
Patent number: 10392419Abstract: Compounds of formula (I) wherein Base1 and Base2 are defined as in claim 1 are modulators of STING.Type: GrantFiled: March 20, 2018Date of Patent: August 27, 2019Assignee: Boehringer Ingelheim International GmbHInventors: Thorsten Oost, Martin Fleck, Christian Andreas Kuttruff, Sebastian Carotta
-
Patent number: 10392420Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.Type: GrantFiled: December 13, 2013Date of Patent: August 27, 2019Assignee: Pfizer Inc.Inventors: Mingming Han, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad
-
Patent number: 10392421Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: GrantFiled: April 24, 2018Date of Patent: August 27, 2019Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang
-
Patent number: 10392422Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: May 19, 2015Date of Patent: August 27, 2019Assignees: RQX PHARMACEUTICALS, INC., GENENTECH, INC.Inventors: Tucker Curran Roberts, Peter Andrew Smith, Robert I. Higuchi, Prasuna Paraselli, Philippe Bergeron, Michael F. T. Koehler, Huiyong Hu, Jacob Bradley Schwarz, Cuong Ly, James John Crawford
-
Patent number: 10392423Abstract: Provided are peptides, compositions comprising the peptides, and methods of using the peptide compositions for inhibition of growth of cancer cells. The peptides comprise a sequence of ARX1X2X3X4, and inhibit or disrupt the formation of MLL1 and SET1 complexes.Type: GrantFiled: March 29, 2018Date of Patent: August 27, 2019Assignee: The Research Foundation for the State University of New YorkInventors: Michael S. Cosgrove, Nilda L. Alicea-Velazquez, Stephen A. Shinsky
-
Patent number: 10392424Abstract: Modified meningococcal fHbp polypeptides with increased stability.Type: GrantFiled: February 27, 2015Date of Patent: August 27, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Matthew Bottomley, Enrico Malito, Manuele Martinelli, Maria Scarselli
-
Patent number: 10392425Abstract: The present invention provides multivalent CD20-binding molecules, and compositions thereof, such as enriched compositions comprising large proportions of multivalent CD20-binding molecule relative to monovalent CD20-binding molecule. Certain multivalent CD20-binding molecules of the present invention comprise 1) two or more CD20 binding regions and 2) one or more Shiga toxin effector polypeptide regions derived from an A Subunit of a member of the Shiga toxin family. Certain multivalent CD20-binding molecules of the present invention, and compositions thereof, have uses for selective killing specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, tumors, and immune disorders.Type: GrantFiled: February 4, 2016Date of Patent: August 27, 2019Assignee: Molecular Templates, Inc.Inventors: Eric Poma, Erin Willert, Jason Kim, Jack Higgins, Jensing Liu, Rodney Flores-Lefranc
-
Patent number: 10392426Abstract: The invention, in some aspects relates to light-activated ion channel polypeptides and encoding nucleic acids and also relates in part to compositions comprising light-activated ion channel polypeptides and methods using light-activated ion channel polypeptides to alter cell activity and function.Type: GrantFiled: February 6, 2015Date of Patent: August 27, 2019Assignees: Massachusetts Institute of Technology, The Governors of the University of Alberta, President and Fellows of Harvard CollegeInventors: Nathan Klapoetke, Edward Boyden, Yongku Cho, Brian Y. Chow, Gane K. S. Wong, Adam E. Cohen, Daniel R. Hochbaum
-
Patent number: 10392427Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: April 19, 2019Date of Patent: August 27, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Colette Song, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
-
Patent number: 10392428Abstract: The invention relates to a derivative of a GLP-1 analog of a general Formula I, which derivative comprises a side chain attached to a Lys residue at position 34, 35, 36, 37, 38, or 39 of the GLP-1 analog. The side chain comprises a Branched linker, a 1st and a 2nd Protractor and a Pre-linker. The Branched linker is connected to the Lys residue of the GLP-1 analog via the Pre-linker and to the 1st and the 2nd Protractor via a 1st and 2nd Post-linker, respectively. The Branched linker may, e.g., be a tri-radical of Lys. The 1st and the 2nd Protractor is C20 diacid. Various linker elements may be used in the Prelinker as well as the two Post-linkers. The invention also relates to novel GLP-analogs, novel side chain intermediates and their manufacture and use to prepare derivatives of biologically active peptides and proteins, as well as pharmaceutical compositions and medical uses of the analogs and derivatives.Type: GrantFiled: December 17, 2015Date of Patent: August 27, 2019Assignee: Novo Nordisk A/SInventor: Jacob Kofoed
-
Patent number: 10392429Abstract: A single-chain insulin comprises a C-domain of 6 to 11 amino acid residues comprising at least two acidic residues at the N-terminal side of the C-domain and at least two basic residues at the C-terminal side of the C-domain peptide, a basic amino acid residue at the position corresponding to A8 of human insulin, and an acidic amino acid residue at the position corresponding to A14 of human insulin. The C-domain may contain a 2 to 4 amino acid joint region between the acidic and basic residues. Residues C1 and C2 may have a net negative charge of ?1 or ?2; and the remaining C-domain segment may culminates with two basic residues. A pharmaceutical composition comprises the single-chain insulin, formulated at a pH within the range 7.0 to 8.0, and may be formulated at a concentration of 0.6 mM to 5.0 mM and/or at a strength of U-100 to U-1000.Type: GrantFiled: October 6, 2015Date of Patent: August 27, 2019Assignee: Case Western Reserve UniversityInventor: Michael Weiss
-
Patent number: 10392430Abstract: The present invention provides VEGF antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing VEGF activity is provided comprising a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component.Type: GrantFiled: June 16, 2017Date of Patent: August 27, 2019Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
-
Patent number: 10392431Abstract: The receptor for Interleukin 35 (IL-35) is provided. The Interleukin 35 Receptor (IL-35R) comprises a heterodimeric complex of the Interluekin12R?2 receptor and the gp130 receptor. Various compositions comprising the IL-35R complex, along with polynucleotides encoding the same and kits and methods for the detection of the same the same are provided. Methods of modulating the activity of IL-35R or modulating effector T cell functions are also provided. Such methods employ various IL-35R antagonists and agonists that modulate the activity of the IL-35R complex and, in some embodiments, modulate effector T cell function. Further provided are methods for screening for IL-35R binding agents and for IL-35R modulating agents. Various methods of treatment are further provided.Type: GrantFiled: February 13, 2017Date of Patent: August 27, 2019Assignee: St. Jude Children's Research HospitalInventors: Dario A.A. Vignali, Lauren Collison
-
Patent number: 10392432Abstract: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing influenza virus activity, thus providing a means of treating or preventing influenza infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the influenza HA for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.Type: GrantFiled: December 18, 2015Date of Patent: August 27, 2019Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Lisa A. Purcell, Jonathan Viau, William Olson
-
Patent number: 10392433Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: GrantFiled: June 12, 2018Date of Patent: August 27, 2019Assignees: The Rockefeller University, California Institute of TechnologyInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Patent number: 10392434Abstract: Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.Type: GrantFiled: September 22, 2017Date of Patent: August 27, 2019Assignee: Teva Pharmaceuticals International GmbHInventors: Marcelo Bigal, Ernesto Aycardi
-
Method for decreasing depression-like behavior with connective tissue growth factor (CTGF) inhibitor
Patent number: 10392435Abstract: The methods of the present invention are useful for determining whether an individual has or is at risk of developing an affective disorder by detecting the expression level of connective tissue growth factor (CTGF) in a biological sample. The methods of the present invention are also useful for identifying compounds that modulate (e.g., decrease) the expression level or activity of CTGF. The present invention further provides therapeutic methods that target CTGF for the treatment of an affective disorder.Type: GrantFiled: December 6, 2017Date of Patent: August 27, 2019Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Huda Akil, Stanley Watson, Cortney Turner -
Patent number: 10392436Abstract: The present application discloses a novel anti-human IL-17 monoclonal antibody obtained by phage antibody library screening and genetic engineering, or a functional fragment thereof, a polynucleotide encoding the monoclonal antibody or the functional fragment thereof, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or vector, a method for preparing and purifying the antibody, and use of the antibody or the functional fragment thereof.Type: GrantFiled: February 29, 2016Date of Patent: August 27, 2019Assignees: BEIJING BETTERMAB BIOTECHNOLOGY CO., LTD, BEIJING WISDOMAB BIOTECHNOLOGY CO., LTD, GENRIX (SHANGHAI) BIOPHARMACEUTICAL CO. LTD., CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD.Inventors: Zhigang Liu, Shijie Shen, Yulan Liu, Jingjing Guo, Xiaobo Hao
-
Patent number: 10392437Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.Type: GrantFiled: November 21, 2016Date of Patent: August 27, 2019Assignee: École Polytechnique Fédérale de Lausanne (EPFL)Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Patent number: 10392438Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.Type: GrantFiled: May 13, 2015Date of Patent: August 27, 2019Assignee: PFIZER INC.Inventors: Eric M. Bennett, Nathan Higginson-Scott, Lioudmila Tchistiakova, Kimberly A. Marquette, Janet E. Paulsen, Ruth E. Gimeno
-
Patent number: 10392439Abstract: The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) antagonist such as an anti-IL-4R? antibody.Type: GrantFiled: June 3, 2014Date of Patent: August 27, 2019Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Neil Stahl, Jamie M Orengo, Andrew J. Murphy, Namita Gandhi, Neil Graham
-
Patent number: 10392440Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: GrantFiled: February 12, 2016Date of Patent: August 27, 2019Assignee: Ablynx N.V.Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
-
Patent number: 10392441Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7R? are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7R? using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7R?, such as acute lymphoblastic leukemia.Type: GrantFiled: October 7, 2016Date of Patent: August 27, 2019Assignees: United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland, College ParkInventors: Scott Durum, Julie Hixon, Wen Qing Li, Scott Walsh, Lila Kashi
-
Patent number: 10392442Abstract: This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.Type: GrantFiled: December 19, 2016Date of Patent: August 27, 2019Assignees: Bristol-Myers Squibb Company, Celldex Therapeutics, Inc.Inventors: Vladimir Coric, Tibor Keler, Thomas Davis
-
Patent number: 10392443Abstract: Disclosed is a method for determining the likelihood of the presence or progression of a hepatocellular carcinoma in a subject, comprising determining the level of extracellular form of Agrin in an extracellular fluid obtained from the subject. Also disclosed are the use of anti Agrin agent for therapy, a pharmaceutical composition comprising anti-Agrin agent, a method of treating cancer comprising an anti-Agrin agent, a use of anti-Agrin agent and a kit thereof.Type: GrantFiled: June 2, 2015Date of Patent: August 27, 2019Assignee: Agency for Science, Technology and ResearchInventors: Sayan Chakraborty, Wanjin Hong
-
Patent number: 10392444Abstract: The present disclosure relates to a method for inhibiting cancer tumor growth in a patient by administering to the patient a therapeutic monoclonal antibody specific for a tumor associated antigen in combination with at least one immunostimulatory compound, and at least one immune homeostatic checkpoint inhibitor. Also disclosed are uses, compositions and kits thereof.Type: GrantFiled: August 7, 2015Date of Patent: August 27, 2019Assignee: Oncoquest, Inc.Inventors: Ragupathy Madiyalakan, Christopher F Nicodemus
-
Patent number: 10392445Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.Type: GrantFiled: March 10, 2016Date of Patent: August 27, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
-
Patent number: 10392446Abstract: The present disclosure provides compositions and methods that rapidly and selectively modify cells of the immune system to achieve therapeutic objectives. The methods can be practiced in vivo and any cell type that expresses a known marker can be targeted for a therapeutic objective.Type: GrantFiled: August 8, 2017Date of Patent: August 27, 2019Assignee: FRED HUTCHINSON CANCER RESEARCH CENTERInventor: Matthias Stephan
-
Patent number: 10392447Abstract: Provided are novel human-derived dipeptide repeat (DPR) specific antibodies as well as synthetic variants and biotechnological derivatives thereof, preferably capable of binding C9ORF72 DPRs, as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for DPRs and DPR proteins such C9ORF72 DPRs are also disclosed. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.Type: GrantFiled: September 30, 2015Date of Patent: August 27, 2019Assignee: Neurimmune Holding AGInventors: Fabio Montrasio, Jan Grimm
-
Patent number: 10392448Abstract: A method for grafting a carboxylic acid ester function onto an unsaturated polymer, which comprises the reaction of a 1,3-dipolar compound with at least one unsaturation of the unsaturated polymer is provided. The 1,3-dipolar compound comprises a group Q and a group B connected to one another by a group A in which: Q comprises a dipole containing at least and preferably one nitrogen atom, B represents a carboxylic acid ester function, A, which is preferably divalent, is an atom or a group of atoms connecting Q to B.Type: GrantFiled: May 19, 2015Date of Patent: August 27, 2019Assignees: COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN, MICHELIN RECHERCHE ET TECHNIQUE, S.A.Inventor: Anne-Frédérique Salit
-
Patent number: 10392449Abstract: The present invention relates to a polymerization initiator represented by Formula 1, a modified conjugated diene-based polymer, methods for preparing them, a rubber composition comprising the modified conjugated diene-based polymer, and a tire prepared from the rubber composition. (In Formula 1, the definition of each substituent is the same as defined in the description.Type: GrantFiled: November 2, 2016Date of Patent: August 27, 2019Assignee: LG Chem, Ltd.Inventors: Min Sik Mun, No Ma Kim, Ho Young Lee
-
Patent number: 10392450Abstract: A process to form a block copolymer comprising two or more regions or segments of differentiated polymer composition or properties, including feeding a first mixture that includes a chain shuttling agent, a solvent, the one or more monomers, and optionally hydrogen into a first reactor or reactor zone, feeding a second mixture that includes at least one olefin polymerization catalyst and at least one cocatalyst into the first reactor or reactor zone, contacting the first mixture and the second mixture under polymerization conditions in the first reactor or reactor zone to form a reaction mixture that is characterized by the formation of polymer chains from the monomers, allowing polymerization to occur in the first reactor or reactor zone and/or a second reactor or reactor zone to form polymer chains that are differentiated from the polymer chains, such that the resultant polymer has two or more chemically or physically distinguishable blocks.Type: GrantFiled: March 22, 2016Date of Patent: August 27, 2019Assignee: Dow Global Technologies LLCInventors: Thomas W. Karjala, Brandon Fails, Jacob Veldman, Curvel Hypolite, James B. Crim, Anthony J. Castelluccio, Ludovicus J C Sluijts, Pradeep Jain
-
Patent number: 10392451Abstract: The present invention relates to a ligand compound, catalyst system for olefin oligomerization, and a method for oligomerizing olefins using the same. The catalyst system for olefin oligomerization according to the present invention exhibit selectivity to 1-hexene or 1-octene while having excellent catalytic activity, thus enabling more efficient preparation of alpha-olefins.Type: GrantFiled: December 21, 2015Date of Patent: August 27, 2019Assignee: LG Chem, Ltd.Inventors: Seok Pil Sa, Yong Ho Lee, Eun Ji Shin, Ki Soo Lee, Jin Young Park, Seul Ki Im
-
Patent number: 10392452Abstract: A self-healing polymeric material includes a polymeric matrix material, a plurality of monomer mixture microcapsules dispersed in the polymeric matrix material, and a plurality of light generating microcapsules dispersed in the polymeric matrix material. Each monomer mixture microcapsule encapsulates a mixture of materials that includes monomers and a photoinitiator. Each light generating microcapsule encapsulates multiple reactants that undergo a chemiluminescent reaction. The chemiluminescent reaction generates a photon having a wavelength within a particular emission range that is consistent with an absorption range of the photoinitiator.Type: GrantFiled: June 23, 2017Date of Patent: August 27, 2019Assignee: International Business Machines CorporationInventors: Eric J. Campbell, Sarah K. Czaplewski, Joseph Kuczynski, Timothy J. Tofil
-
Patent number: 10392453Abstract: A method for producing an olefin polymerization catalyst includes bringing a solid catalyst component for olefin polymerization, a vinylsilane compound, an organosilicon compound, and an organoaluminum compound into contact with each other in an inert organic solvent under an inert gas atmosphere in the absence of a specific vinyl compound, wherein a washing treatment is not performed after the vinylsilane compound has been added to the reaction system, the solid catalyst component includes a magnesium compound, a titanium halide compound, and an electron donor compound that does not include a phthalic acid ester structure, and includes a diol skeleton, and the organosilicon compound does not include a vinyl group, and includes at least one group selected from an alkoxy group and an amino group.Type: GrantFiled: January 18, 2016Date of Patent: August 27, 2019Assignee: TOHO TITANIUM CO., LTD.Inventors: Hiroyuki Kono, Toshiya Uozumi, Shingo Yamada, Toshihiko Sugano
-
Patent number: 10392455Abstract: A method of controlling the polymer composition of an ethylene copolymer in a process for preparing ethylene copolymers by copolymerizing ethylene and at least one other olefin in the presence of a polymerization catalyst system comprising at least one late transition metal catalyst component (A), at least one Ziegler catalyst component (B), and at least one activating compound (C) by adding an alkyl alkoxy silane or a dialkyl ether for increasing the relative portion of the ethylene copolymer component obtained from polymerization by late transition metal catalyst component (A), or by adding a saturated halogenated hydrocarbon for increasing the relative portion of the ethylene copolymer component obtained from polymerization by Ziegler catalyst component (B), processes for copolymerizing ethylene and at least one other olefin in the presence of such a polymerization catalyst system comprising utilizing the controlling method, a method for altering the polymer composition of an ethylene copolymer obtaiType: GrantFiled: December 17, 2012Date of Patent: August 27, 2019Assignee: Basell Polyolefine GmbHInventors: Marc Oliver Kristen, Lenka Richter-Lukesova
-
Patent number: 10392456Abstract: Catalyst systems and methods for making and using the same. A method of methylating a catalyst composition while substantially normalizing the entiomeric distribution is provided. The method includes slurrying the organometallic compound in dimethoxyethane (DME), and adding a solution of RMgBr in DME, wherein R is a methyl group or a benzyl group, and wherein the RMgBr is greater than about 2.3 equivalents relative to the organometallic compound. After the addition of the RMgBr, the slurry is mixed for at least about four hours. An alkylated organometallic is isolated, wherein the methylated species has a meso/rac ratio that is between about 0.9 and about 1.2.Type: GrantFiled: February 26, 2018Date of Patent: August 27, 2019Assignee: Univation Technologies, LLCInventors: Francis C. Rix, Alexander D. Todd, C. Jeff Harlan
-
Patent number: 10392457Abstract: The present invention relates to a method of preparing a thermoplastic resin. More particularly, the present invention relates to a method of preparing a thermoplastic resin, the method including a coagulation step of adding a water-soluble silicate compound and a metal salt coagulant to an ?-methylstyrene-vinyl cyan compound copolymer latex, followed by coagulation. In accordance with the present invention, a method of preparing a thermoplastic resin having superior heat resistance by adding an additive during coagulation and aging of ?-methylstyrene-vinyl cyan compound copolymer latex while controlling an addition time point of the additive is provided.Type: GrantFiled: September 8, 2016Date of Patent: August 27, 2019Assignee: LG CHEM, LTD.Inventors: Sung Won Hong, Hyung Sub Lee, Min Cheol Ju, Min Seung Shin, In Soo Kim
-
Patent number: 10392458Abstract: Disclosed are a resin blend, a copolymer, a pellet, a method of manufacturing a resin-molded article using the same, and a resin-molded article. The exemplary resin blend can be useful in providing a protective film for polarizing plates having excellent adhesive strength to a polarizer. Also, the resin blend can be useful in exhibiting excellent adhesive strength to the polarizer without performing an additional primer coating process on a surface(s) of the protective film for polarizing plate, thereby reducing production time and cost and improving productivity.Type: GrantFiled: July 8, 2014Date of Patent: August 27, 2019Assignee: LG Chem, Ltd.Inventors: Eun Joo Choi, Jin Young Ryu, Jong Won Lee, Kyoung Hoon Kim, Hyeon Choi
-
Patent number: 10392459Abstract: The present invention relates to: a photocurable composition containing (A) a photocurable monomer and (B) a monomer containing phosphorus and an amide group; and a device including a barrier layer formed of the composition.Type: GrantFiled: July 8, 2013Date of Patent: August 27, 2019Assignee: CHEIL INDUSTRIES, INC.Inventors: Ji Hye Kwon, Hyo Young Kwon, Seong Ryong Nam, Se Il Oh, Chang Soo Woo, Yeon Soo Lee, Chang Min Lee, Seung Jib Choi, Kyoung Jin Ha